Options Medical Weight Loss Review

What Options Medical Weight Loss charges

• NAD+: $199/mo — per month, printed on the product page directly beneath the compounding disclaimer
• Glutathione: $179/mo — per month, on its own product page

Two peptides priced where they are sold

NAD+ and glutathione each have their own product page, and each prints a monthly figure on it.

Beneath each figure is a line saying the formulation is compounded by a licensed compounding pharmacy and that the FDA does not review or approve compounded medications for safety or effectiveness.

Putting the disclaimer under the price rather than in a footer is a small thing that changes what a reader sees at the moment of deciding.

The weight-loss figures buy a programme

Its two weight-loss offers are described as a three-phase plan with prescription medicine, nutrition guidance and metabolism support, priced from a starting figure with medication included.

A programme floor is not a drug price. Filing it under semaglutide or tirzepatide would publish the cost of nutrition coaching as the cost of a medicine.

Both drugs are declared, because the seller genuinely dispenses them. Neither carries a price on this record.

What it says about its supply

It says its weight-loss injections are made in FDA-regulated 503B outsourcing facilities in the United States.

That names a facility category rather than a facility, so no pharmacy is credited as named here.

It also names the two manufacturers of the approved versions of the drugs it prescribes, and distinguishes them from what it compounds.

The gaps

No list of served states is published.

No dispensing pharmacy is named.

No certificate of analysis is reachable, and no tracked peptide other than NAD+ and glutathione is sold. A meaningless address on this host returns a not-found response, so those absences are absences.

How we verified this

• Read each peptide product page and recorded the figure printed on it, with the disclaimer that sits beneath it.
• Read the weight-loss offers, found that each figure buys a three-phase programme, and filed neither under a drug.
• Recorded the facility-category claim as a category rather than crediting a named pharmacy.
• Requested a deliberately meaningless address on this host in the same session and confirmed it returns a not-found response.
• Screened the brand against the live federal warning-letter table, filtering locally because the table's own search parameter returns every record whatever is typed into it, with a positive and a nonsense control in the same run.